Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

One shipment of suspected counterfeit Wegovy was hidden inside a Mickey Mouse puzzle for ... FDA has not approved any generic versions of semaglutide." Eli Lilly, makers of Mounjaro and Zepbound, also ...

In the study, 33.4% of patients taking Wegovy were admitted, compared to about 37% in the placebo cohort. Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo ...

Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 drugs like Wegovy and Zepbound. To catch full episodes of all The Motley Fool's free podcasts, check out our ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...